TECHWIRE 30
(CIX: WRAL30)  1,121.81  up arrow+3.45  (0.31 %)  Updated: 08:10 PM EDT, Jul 01 2016
(NQ: Apple)  95.89  up arrow+0.29  (0.3 %)  Updated: 08:10 PM EDT, Jul 01 2016
(NY: Q)  66.86  up arrow+1.54  (2.36 %)  Updated: 08:04 PM EDT, Jul 01 2016
(OP: BASFY)  77.21  up arrow+0.51  (0.66 %)  Updated: 05:20 PM EDT, Jul 01 2016
(NQ: BCRX)  2.94  up arrow+0.1  (3.52 %)  Updated: 08:10 PM EDT, Jul 01 2016
(NQ: BDSI)  2.40  up arrow+0.04  (1.69 %)  Updated: 08:10 PM EDT, Jul 01 2016
(NQ: CEMP)  17.09  up arrow+0.6  (3.64 %)  Updated: 08:10 PM EDT, Jul 01 2016
(NQ: Cisco)  28.80  up arrow+0.11  (0.38 %)  Updated: 08:10 PM EDT, Jul 01 2016
(NQ: CREE)  24.51  up arrow+0.07  (0.29 %)  Updated: 08:10 PM EDT, Jul 01 2016
(NQ: DARA)  0.88    (0 %)  Updated: 08:10 PM EST, Dec 04 2015
(NY: EMC)  27.35  up arrow+0.18  (0.66 %)  Updated: 08:04 PM EDT, Jul 01 2016
(NQ: EXTR)  3.45  up arrow+0.06  (1.77 %)  Updated: 08:10 PM EDT, Jul 01 2016
(NQ: Facebook)  114.19  down arrow-0.09  (-0.08 %)  Updated: 08:10 PM EDT, Jul 01 2016
(NY: GSK)  43.17  down arrow-0.17  (-0.39 %)  Updated: 08:04 PM EDT, Jul 01 2016
(NQ: Alphabet)  699.21  up arrow+7.11  (1.03 %)  Updated: 08:10 PM EDT, Jul 01 2016
(NY: IBM)  152.35  up arrow+0.57  (0.38 %)  Updated: 08:04 PM EDT, Jul 01 2016

Posts tagged “Quintiles”

June 24

Triangle headlines: RTI-Zika research; Quintiles glucose monitoring; Cree's LED plant lights; PatientPay exec; Q2 award

Triangle headlines Triangle headline news this week includes: RTI to host Zika research; Quintiles offers new glucose monitoring service; Cree offers new LEDS to boost plants; PatientPay adds a new exec; and Quintiles joint venture Q2 wins an award.

June 21

Premium Lock Quintiles launches accelerator for healthcare apps development

Quintiles aims to speed up development for apps to boost healthcare with a new "Solution Design Studio." The accelerator's team will work with Quintiles clients in a variety of initiatives such as virtual reality and wearables.

Updated June 13

IMS merger could make Quintiles CEO $16.4M richer

Tom Pike Tom Pike, chief executive officer of life science giant Quintiles, stands to make more than $16 million in cash and stock if Quintiles' merger with IMS Holdings wins shareholders' approval - and he stays with the company through 2017.

Updated June 8

Triangle headlines: NC in Fortune 500; TWC being 'bullied;' H-1Bs in Charlotte; Metabolon deal

Triangle headlines In our latest wrapup of Triangle headlines from other publications, catch up on reports about the new Fortune 500 and what North Carolina firms made it as well as news about Time Warner Cable, Metabolon and an investigation into H-1B visas in Charlotte.

June 3

Tech in brief: Quintiles enrollment; INC's new chair; CED venture pitches; Home Care Assist

Triangle technology briefs: Quintiles launches a precision enrollment program for oncology trials; INC Research's veteran cahir and former CEO retires, and a current board member takes over; the CED is looking for startups who want to pitch investors at its annual venture capital event; and a new home care screening service launches in Raleigh.

Updated May 24

Premium Lock 'Wow:' Quintiles takes vivid VR plunge to improve digital health

Darrell Pryor, news photographer for WRAL TV, utters a "wow" and smiles as he removes the virtual reality goggles during the first VR demo given by Quintiles to news media about its new VR initiative. But Quintiles isn't playing games. It's aiming to improve the clinical trials process and digital health. "We feel we are out there at the edge," says the Quintiles exec leading the VR charge. "People come out of the experience different." Indeed, they do.

May 20

Premium Lock Clinical trial of the future: How secondary data could add speed and accuracy to trial designs

On International Clinical Trials day, Cynthia Verst, the president of Clinical Operations at Quintiles, writes that the use of secondary data earlier in the research process can lead to "smarter, faster and more cost-sensitive clinical trials."

Cynthia Verst Cynthia Verst

Updated May 16

Premium Lock Profiling CED's first four Entrepreneur Hall of Famers

In announcing the first four selections for the new Entrepreneur Hall of Fame, the Council for Entrepreneurial development also provides succinct biographies. Here they are - with photos.

Dennis Gillings, center, rings in NYSE action Dennis Gillings, center, rings in NYSE action

Updated May 13

Premium Lock CED Entrepreneur Hall of Fame picks pioneers Dougherty, Gillings, Hutchison, Young

The Council for Entrepreneurial Development's new Hall of Fame is kicking off with a powerful lineup of honorees: The father of venture capital in North Carolina, the co-founder of Quintiles, a longtime tech industry lawyer, and the irrepressible co-founder of Red Hat.

CED CED

Updated May 5

Premium Lock Countering downgrades, S&P gives Quintiles a post-merger boost

Quintiles            Three Wall Street firms have voted "no" on the big Quintiles-IMS Health merger so far by downgrading Quintiles stock. However, on Wednesday afternoon S&P Global Ratings weighed in with a positive review of the deal. WTW Insiders get the details.

Updated May 4

Premium Lock Quintiles, IMS to merge, forming $17.6B firm; Street lukewarm to deal

Durham-based life science services giant Quintiles is merging with IMS Health Holdings in a deal forming a company worth some $17.6 billion. The merger was announced early Tuesday. Quintiles founder Dennis Gillings will lead the combined board but IMS shareholders will hold majority of stock. Wall Street, however, reacts negatively to the news.

Quintiles' headquarters       Quintiles' headquarters

Updated May 4

Premium Lock CEOs' meeting leads to huge $17.6B Quintiles-IMS merger

The merger of Quintiles and IMS Health creating a $17 billion health services company announced Tuesday can be traced back to a meeting between the two CEOs last year. Quintiles' Tom Pike tells analysts the two firms discovered quickly how well they could work together, and the CEO of IMS says the collaboration has already delivered "major wins."

Tom Pike Tom Pike

Updated May 3

Premium Lock Analyst: Q-IMS merger could trigger more deals; why Street doesn't like Q deal

Tech mergers Tuesday's merger of Quintiles with IMS Health Services might trigger other CRO deals affecting the Triangle, says Chapel Hill-based analyst Andrew Schafer of Industry Standard Research. Also, Wall Street is giving the Q deal the thumbs down as shares tumble 8 percent. Why? Schafer explains. Plus, a Bloomberg columnist weighs in.

May 3

Premium Lock Quintiles merger Q&A: Local impact, why do the deal, more

Merger Any time companies merger, they talk about cost savings and "synergies." That often means layoffs with redundant services and more often being cut. So will there be an immediate impact in Durham at Quintiles' global headquarters? And why merge with IMS Health Services? WTW asks a Quintiles exec for details.

Updated March 4

Premium Lock Quintiles to work with American College of Surgeons on data in attempt to improve patient outcomes

Quintiles            Quintiles has signed a services agreement with the American College of Surgeons to compile and use ACS data in an attempt to improve patient outcomes through a clinical registry platform.

March 4

Premium Lock Quintiles mulls closing clinical trial unit in London

Quintiles is proposing to shut down a Phase 1 clinical trial unit in London which employs some 170 doctors and other staff, a company spokesperson tells WRAL TechWire.

Quintiles' European HQ Quintiles' European HQ

Updated February 22

Premium Lock Quintiles is 'Most Admired' life sciences firm; IBM, AT&T crack top 50 Fortune list

Fortune's latest "Most Admired Companies" report includes Quintiles for the second straight year. IBM and AT&T crack the overall top 50, and Lenovo comes in at No. 3 among technology firms. Meanwhile, three "As" finished 1-2-3.

Fortune "Most Admired" Fortune "Most Admired"

Updated February 11

Premium Lock Quintiles earnings beat Street forecasts; CEO upbeat

Quintiles            Quintiles reports quarterly earnings that top Wall Street expectations, and the business pipeline has CEO Tom Pike upbeat. "We believe we are well-positioned for the long-term with our $12.04 billion of backlog," he says.

February 4

Premium Lock Quintiles exec on immunotherapy: 'It's working'

Cancer research  In observance of Feb. 4 as "World Cancer Day," Terry Murdock, the head of the Oncology Center of Excellence at Quintiles, writes in a blog that "there is much to celebrate" this year in the fight against cancer.

Updated January 14

Premium Lock Quintiles defends company, CROs despite stock drops

With "apathetic" attitudes helping drive down life science industry stocks as part of a general market spiral, Quintiles CEO Tom Pike took to the airways Wednesday evening to defend his company and the biotech-related sector.

Quintiles' dropping stock Quintiles' dropping stock

Techwire Inside Partners
The Skinny: A Blog by Rick Smith